We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
- Authors
Dang, Nam H.; Fayad, Luis; McLaughlin, Peter; Romaguara, Jorge E.; Hagemeister, Fredrick; Goy, Andre; Neelapu, Sattva; Samaniego, Felipe; Walker, Pamela L.; Wang, Michael; Rodriguez, Maria A.; Tong, Ann T.; Pro, Barbara
- Abstract
Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma patients. Of the 38 evaluable patients, 30 (80%) were rituximab-refractory. The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR). The median time to progression for responders was 8 months (range: 2–36+); two patients with rituximab-refractory follicular lymphoma were in CR at 25 and 36+ months. The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon.
- Subjects
RITUXIMAB; ANTINEOPLASTIC agents; MONOCLONAL antibodies; HODGKIN'S disease; B cell lymphoma; LYMPHOPROLIFERATIVE disorders
- Publication
British Journal of Haematology, 2007, Vol 138, Issue 4, p502
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2007.06684.x